LIR Life Sciences Corp. SKNY
CNSX
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -26.53% | -- | |||
| Gross Profit | 26.53% | -- | |||
| SG&A Expenses | -39.52% | -35.71% | |||
| Depreciation & Amortization | -- | -10.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.83% | -32.85% | |||
| Operating Income | 21.83% | 32.85% | |||
| Income Before Tax | 30.55% | 34.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.55% | 34.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.55% | 34.62% | |||
| EBIT | 21.83% | 32.85% | |||
| EBITDA | 21.85% | 32.87% | |||
| EPS Basic | 31.77% | 35.82% | |||
| Normalized Basic EPS | 26.67% | 41.67% | |||
| EPS Diluted | 31.77% | 35.82% | |||
| Normalized Diluted EPS | 26.67% | 41.67% | |||
| Average Basic Shares Outstanding | 1.62% | 1.89% | |||
| Average Diluted Shares Outstanding | 1.62% | 1.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||